- With CGM now part of Canadian Diabetes Clinical Practice Guidelines, Use of Dexcom CGM has been shown to improve blood sugar control1,2 It can reduce the risk of costly complications related to diabetes in the long term compared to fingertip monitoring.3
Burnaby, British Columbia – Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time glucose monitoring (rtCGM), today reports that people with type 1 and type 2 diabetes aged 2 years and older are taking multiple daily insulin injections. Those (three or more) or those using an insulin pump may now be eligible for general coverage of the Dexcom G6 CGM System through the PEI Diabetes Glucose Sensing Program.
Prince Edward Island joins British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Yukon, and the Uninsured Health Benefits Program [NIHB] in providing publicly funded coverage of Dexcom CGM, one of only two government programs [with BC PharmaCare] To provide general coverage to eligible children and adults with type 1 or type 2 diabetes.
Today’s announcement represents meaningful progress in achieving better access to real-time CGM technology for all Canadians with diabetes. We thank the PEI government for setting a precedent that everyone who receives multiple daily injections of insulin deserves access to this technology. Managing diabetes can make everyday life a challenge, regardless of an individual’s age, and now people with diabetes who meet the eligibility criteria in PEI can manage their condition more effectively, freely and with confidence,” says Laura Endres, Senior Vice President. Dexcom, North America.
The Dexcom G6 CGM system uses a sensor and a small wearable transmitter to measure glucose levels and send them wirelessly to the monitor; and a compatible smart device* or receiver that displays real-time glucose data to users without the need for calibration† or scanning. The Dexcom G6 CGM system provides users with real-time alerts, including a predictive urgent low soon alert, and can warn the user in advance of hypoglycemia – giving them time to take appropriate action before it occurs. Using the Dexcom Follow . app‡Parents and caregivers can also access their loved one’s glucose levels remotely and be alerted if they are outside their target glucose range. As part of the Diabetes Glucose Sensor Program, users will now be able to order and pick up Dexcom CGM supplies from their local drugstore.
“We commend PEI’s efforts to expand access to transformative diabetes care and provide more options and treatment options to Islanders living with diabetes. Increasing access to advanced glucose monitoring systems such as the Dexcom G6 is critical to improving the overall health and quality of life for people who have diabetes. suffer from type 1 diabetes, says Dave Bruten, president and CEO of JDRF Canada.
In 2021, a Diabetes Clinical Practice Guidelines in Canada The review committee updated its recommendations for glucose monitoring, stating that a real-time CGM (rtCGM), such as the Dexcom G6, should be used by individuals with type 1 diabetes treated with basal insulin injections or an insulin pump in order to reduce A1C and increase time-to-term reduce the duration of hypoglycemia and improve quality of life in adults.4 The guidelines also state that adults with type 2 diabetes who use the basal bolus but not the target may use rtCGM to reduce A1C and duration of hypoglycemia.5
For more information about the coverage criteria for the Diabetes Glucose Sensor Program, please visit https://www.dexcom.com/en-CA/public-coverage#pei or this FAQ on the Prince Edward Island Health website.
About Dexcom, Inc.
Dexcom empowers people to control diabetes with innovative glucose monitoring (CGM) systems. Dexcom is headquartered in San Diego, California in the United States, with operations in Canada, and has emerged as a leader in diabetes care technology. By listening to the needs of users, caregivers and service providers, Dexcom is simplifying and improving diabetes management around the world. For more information on Dexcom CGM, visit www.dexcom.com.
† If your G6 glucose alerts and readings don’t match your symptoms or expectations, use your blood glucose meter to make diabetes treatment decisions.
* For a list of compatible devices, please visit dexcom.com/compatibility
‡ The following requires the Dexcom Follow app and an internet connection. Followers should always confirm readings on the Dexcom G6 app or receiver before making diabetes treatment decisions.
1 Beck RW, Riddlesworth T, Rudy K, et al. The effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. gamma 2017; 317 (4): 371-8.
2 Welsh JB, Gao P, Derdzinski M, et al. Accuracy, usability, and effectiveness comparisons of different continuous glucose monitoring systems. There is diabetes technology 2019; 21 (3): 128-32.
3 Roze S, Isitt J, Smith-Palmer J, Lynch P. Evaluation of the long-term cost-effectiveness of the Dexcom G6 continuous glucose monitor versus self-monitoring of blood glucose in people with type 1 diabetes in Canada. CEOR. 2021; Volume 13: 717-725.
4 Cheng Aiwei, Fig DS, Hu Ji, et al. Monitoring blood glucose in adults and children with diabetes: an update 2021. Canadian Journal of Diabetes. 2021; 45 (7): 580–587.
5 Cheng Aiwei, Fig DS, Hu Ji, et al. Monitoring blood glucose in adults and children with diabetes: an update 2021. Canadian Journal of Diabetes. 2021; 45 (7): 580–587.
Amanda Wagner, 416.219.7407